Effect of general anesthesia on pulmonary function and clinical status on children with cystic fibrosis

Chetan Pandit1, Roumel Valentin, Jonathan De Lima

  • 1Department of Respiratory medicine, The Children's hospital at Westmead, Sydney, Australia; Discipline of Pediatrics and child health, Sydney Medical School, University of Sydney, Sydney, Australia.

Paediatric Anaesthesia
|September 6, 2013
PubMed

Insights

General anesthesia (GA) in children with cystic fibrosis (CF) appears safe, with no significant impact on lung function or clinical status. Modern anesthetic techniques show improved safety compared to historical data for pediatric CF patients.

Area of Science:

  • Pediatric Anesthesiology
  • Cystic Fibrosis Research
  • Pulmonary Medicine

Background:

  • Children with cystic fibrosis (CF) often require general anesthesia (GA) for various procedures.
  • Historical data suggest a high risk of morbidity associated with GA in CF patients.
  • Limited data exist on the safety of current anesthetic agents in pediatric CF populations.

Purpose of the Study:

  • To assess the impact of general anesthesia (GA) on the clinical status and lung function of children with cystic fibrosis (CF).
  • To evaluate the safety of modern anesthetic agents in pediatric CF patients.

Main Methods:

  • Children aged 8-18 years with CF and pulmonary exacerbation were enrolled.
  • Spirometry, forced oscillation technique (FOT), and CF clinical score (CFCS) were measured before and at 24/48 hours after GA.
  • Details of anesthetic agents and duration were recorded.

Main Results:

  • 19 pediatric CF patients underwent GA, primarily using propofol or sevoflurane.
  • No statistically significant changes were observed in spirometry or CFCS post-GA.
  • Forced oscillation technique (FOT) showed decreased resistance and reactance at 24 and 48 hours post-GA.
  • Only two adverse events were reported in the cohort.

Conclusions:

  • General anesthesia (GA) does not appear to cause significant deterioration in airway function for children with mild to moderate CF lung disease.
  • Modern anesthesia techniques demonstrate an improved safety profile for pediatric CF patients compared to historical data.
  • The low complication rate supports the safe use of current anesthetic agents in this population.
Abstract

Related Concept Videos

Stages of General Anesthesia01:22

Stages of General Anesthesia

Various sedation levels offer significant advantages in facilitating procedural interventions for patients undergoing medical or invasive surgical procedures. These levels span from anxiolysis to general anesthesia, providing a spectrum of sedative effects to cater to specific patient needs. Anxiolysis reduces anxiety and is achieved through minimal sedation, enabling patients to remain awake and responsive while feeling more at ease during the procedure. This level can benefit minor...
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
General Anesthesia: Overview01:24

General Anesthesia: Overview

Anesthesia is a medical procedure that uses drugs for CNS suppression to enable painless surgeries and procedures. The selection of anesthetics is influenced by their pharmacokinetic properties, side effects, and patient characteristics. Various types of anesthesia include general, local, regional, spinal, and inhalational.
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Atelectasis II: Pathophysiology01:10

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History